JPRN-UMIN000031921已完成未知
A preliminary study of the effects of a new oral mucosa protective material on chemotherapy- and/or radiation-induced oral mucositis - A preliminary study of a new oral mucosa protective material
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
Compared to baseline, the mean NRS began to decrease at 5 mins after using Episil ,and this effect lasted up to 120 minutes. The protective effects of Episil were observed already 3 to 5 minutes after application.Some patients felt slight soreness or discomfort when applying Episil.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients have tumor region inside oral cavity 2) Patients have severely injured area not due to oral mucositis 3) Patients who are known or suspected CNS tumor, metastasis or invasion to the CNS 4) Patients have started the rescue medications on Day 1 prior to the application of episil(r). 5) Patients who are participating in other clinical trials 6) Female patients who are breast-feeding, pregnancy or planned pregnancy 7) Patients with considerable concern for compliance with the protocol, in the judgment of investigator
研究者
相似试验
已完成
不适用
A preliminary study of the effects of episil(R) oral liquid on chemotherapy- and/or radiation-induced oral mucositisChemotherapy- and/or radiation-induced oral mucositisJPRN-UMIN000029244Okayama University10
招募中
不适用
A preliminary study of the effects of episil(r) oral liquid on chemotherapy- and/or radiation-induced oral mucositisChemotherapy- and/or radiation-induced oral mucositisJPRN-UMIN000030504Osaka University Dental Hospital10
已完成
不适用
A pilot study of the generic drug of Tamsulosin Hydrochloride to evaluate the efficacy for benign prostatic hyperplasia patients with dysuria.benign prostatic hyperplasiaJPRN-UMIN000003907PO MINS20
进行中（未招募）
1 期
A Study, in which patients with advanced hepatocellular carcinoma (HCC) and preserved liver function are treated with a reduced starting dose ofcabozantinib, followed by an increase of dose, after treatment failure of one previous therapyAdvanced stage hepatocellular carcinoma (HCC) patients with preserved liver function in second line therapyEUCTR2020-000775-20-DEFrankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest40
招募中
3 期
Effect of new trial drug on clinical and paraclinical symptoms in COVID-19COVID-19.COVID-19, virus identifiedU07.1IRCT20200509047373N2Health Medicine Chemistry Company120